JP2023514324A5 - - Google Patents

Info

Publication number
JP2023514324A5
JP2023514324A5 JP2022549457A JP2022549457A JP2023514324A5 JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5 JP 2022549457 A JP2022549457 A JP 2022549457A JP 2022549457 A JP2022549457 A JP 2022549457A JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5
Authority
JP
Japan
Prior art keywords
nanocarrier
prodrug
lipid
item
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022549457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514324A (ja
JP7842690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/010005 external-priority patent/WO2021167703A1/en
Publication of JP2023514324A publication Critical patent/JP2023514324A/ja
Publication of JP2023514324A5 publication Critical patent/JP2023514324A5/ja
Priority to JP2025204012A priority Critical patent/JP2026032152A/ja
Application granted granted Critical
Publication of JP7842690B2 publication Critical patent/JP7842690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022549457A 2020-02-19 2021-02-19 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 Active JP7842690B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025204012A JP2026032152A (ja) 2020-02-19 2025-11-26 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062995887P 2020-02-19 2020-02-19
US62/995,887 2020-02-19
PCT/US2021/010005 WO2021167703A1 (en) 2020-02-19 2021-02-19 Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025204012A Division JP2026032152A (ja) 2020-02-19 2025-11-26 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Publications (3)

Publication Number Publication Date
JP2023514324A JP2023514324A (ja) 2023-04-05
JP2023514324A5 true JP2023514324A5 (cg-RX-API-DMAC7.html) 2024-02-27
JP7842690B2 JP7842690B2 (ja) 2026-04-08

Family

ID=75223393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022549457A Active JP7842690B2 (ja) 2020-02-19 2021-02-19 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
JP2025204012A Pending JP2026032152A (ja) 2020-02-19 2025-11-26 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025204012A Pending JP2026032152A (ja) 2020-02-19 2025-11-26 がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Country Status (8)

Country Link
US (3) US11801304B2 (cg-RX-API-DMAC7.html)
EP (2) EP4096716A1 (cg-RX-API-DMAC7.html)
JP (2) JP7842690B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220143063A (cg-RX-API-DMAC7.html)
CN (3) CN121287708A (cg-RX-API-DMAC7.html)
AU (2) AU2021223336B2 (cg-RX-API-DMAC7.html)
CA (1) CA3170142A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021167703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7842690B2 (ja) * 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
CN112669958B (zh) * 2020-12-08 2022-09-09 河北医科大学第二医院 代谢物作为疾病诊断的生物标志物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539748A1 (en) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
WO2006031471A2 (en) 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CA2632799A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
PT104158B (pt) 2008-08-18 2011-02-24 Univ Do Minho Aplicação da monooleína como novo lípido adjuvante em lipofecção
MX389666B (es) 2009-10-16 2025-03-19 Scripps Research Inst Induccion de celulas pluripotentes.
US20130189780A1 (en) 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
CN103857384B (zh) 2011-06-06 2017-07-11 大学健康网络 用于合成卟啉‑磷脂结合物的方法
CN104023749B (zh) 2011-09-14 2019-12-17 西北大学 能穿过血脑屏障的纳米缀合物
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CA2874490C (en) * 2012-05-23 2021-11-16 The Ohio State University Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AU2014278178B2 (en) 2013-06-11 2021-01-21 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
PL3137473T3 (pl) 2014-05-02 2020-06-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pochodne Pt (iv) i zawierające je nanonośniki
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
JP6602847B2 (ja) * 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
WO2018081480A1 (en) * 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN106176609B (zh) * 2016-08-22 2019-10-15 南通大学 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用
IL268995B2 (en) 2017-03-02 2024-02-01 Nat Res Council Canada TGF-B receptor ectodomain fusion compounds and their uses
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CA3063932A1 (en) 2017-05-18 2018-11-12 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
US11046729B2 (en) 2017-10-26 2021-06-29 Southern Research Institute Dipeptide analogs as TGF-beta inhibitors
AU2018431586B2 (en) 2018-07-09 2025-03-20 Synthis Therapeutics, Inc Antibody-ALK5 inhibitor conjugates and their uses
US12448475B2 (en) * 2019-06-21 2025-10-21 The University Of North Carolina At Chapel Hill Drug delivery compositions and applications thereof
JP7842690B2 (ja) * 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Similar Documents

Publication Publication Date Title
CN113645960B (zh) 含有氧化的胆固醇的药物递送系统
US20250195641A1 (en) Immunotherapeutic constructs and methods of their use
US12059500B2 (en) Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
JP6427097B2 (ja) 癌を処置するための組成物および該組成物を製造するための方法
CN116133652A (zh) 制备脂质纳米粒子的方法
JP7566629B2 (ja) ランゲリン+細胞ターゲティング
JP2024515650A5 (cg-RX-API-DMAC7.html)
EP3442542B1 (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
JP7561146B2 (ja) 接着している粒子を有する赤血球に関連する組成物および方法
KR20230004563A (ko) 강력한 암 면역치료제로서 리포좀성 구형 핵산 내 캡슐화된 산화된 종양 세포 용해물
US20190298824A1 (en) Albumin-binding immunomodulatory compositions and methods of use thereof
US20210177871A1 (en) Methods for cancer therapy
JP2023502182A5 (cg-RX-API-DMAC7.html)
CN118215496A (zh) 抗原和药物-脂质缀合物的免疫调节组合
EP3536343A1 (en) Skin fibrosis treatment agent
US20240376479A1 (en) Aptamers for targeted activation of t cell-mediated immunity
KR20240102993A (ko) 암의 면역요법 치료를 위한 cGAS-STING 및 STAT3 경로 조절용 구형 핵산
US20240417738A1 (en) Immunotherapies for the treatment of cancer
JP2026035730A (ja) 免疫療法構築物およびその使用方法